World Orphan Drugs Congress

This just in: 2025 Sponsorship Opportunities Now Available for ! 📣

This is your chance to get your product or solution in front of the biggest names in the and space – from pharma, biotechs, governments, and payers to patients, investors, and patient advocates.

Parexel, PPD | Thermo Fisher Scientific, Volv Global SA, and more have already confirmed their spots! 👀 Get ahead of the game – 𝗹𝗲𝗮𝗿𝗻 𝗮𝗯𝗼𝘂𝘁 𝗼𝘂𝗿 𝘃𝗮𝗿𝗶𝗼𝘂𝘀 𝘀𝗽𝗼𝗻𝘀𝗼𝗿𝘀𝗵𝗶𝗽 𝗹𝗲𝘃𝗲𝗹𝘀 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗳𝗼𝗿 𝟮𝟬𝟮𝟱 𝗮𝗻𝗱 𝘁𝗵𝗲𝗶𝗿 𝗮𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲𝗱 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗯𝘆 𝗱𝗼𝘄𝗻𝗹𝗼𝗮𝗱𝗶𝗻𝗴 𝗼𝘂𝗿 𝘀𝗽𝗼𝗻𝘀𝗼𝗿𝘀𝗵𝗶𝗽 𝗯𝗿𝗼𝗰𝗵𝘂𝗿𝗲 𝗵𝗲𝗿𝗲: https://tinyurl.com/3w2jwvew

𝗜𝗻𝗾𝘂𝗶𝗿𝗲 𝘁𝗼𝗱𝗮𝘆 𝘁𝗼 𝘀𝗲𝗰𝘂𝗿𝗲 𝘆𝗼𝘂𝗿 𝗽𝗿𝗲𝗺𝗶𝗲𝗿 𝘀𝗽𝗼𝘁 𝗼𝗻 𝗼𝘂𝗿 𝟮𝟬𝟮𝟱 𝗲𝘅𝗽𝗼 𝗳𝗹𝗼𝗼𝗿: https://tinyurl.com/sabm7cx7

Lets work together to advance orphan drug development and improve access to life-saving therapies for rare disease patients worldwide 🌎✨

𝗦𝗮𝘃𝗲 𝘁𝗵𝗲 𝗗𝗮𝘁𝗲! The World Orphan Drug Congress USA is returning to Boston next spring for our 2025 edition.
🗓️ Boston Convention & Exhibition Center
📍 April 22-24, 2025

Now's the perfect time to secure your spot at the world's most important rare disease and orphan drug event before the rush❗️

⭐️ Gather your friends, family, peers, colleagues, and fellow rare disease enthusiasts and 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗮𝘀 𝗮 𝗴𝗿𝗼𝘂𝗽 𝘁𝗼 𝘀𝗮𝘃𝗲 𝘂𝗽 𝘁𝗼 𝟱𝟬% 𝗼𝗻 𝘆𝗼𝘂𝗿 𝘁𝗶𝗰𝗸𝗲𝘁𝘀: https://tinyurl.com/4x3nwttm
⭐️ Patient advocacy groups & hospitals, 𝗰𝗹𝗮𝗶𝗺 𝘆𝗼𝘂𝗿 𝗙𝗥𝗘𝗘 𝗽𝗮𝘀𝘀 𝘁𝗼𝗱𝗮𝘆: https://tinyurl.com/3rxeefp7

⭐️ Looking to sponsor? 𝗦𝗲𝗰𝘂𝗿𝗲 𝘆𝗼𝘂𝗿 𝗽𝗿𝗲𝗺𝗶𝗲𝗿 𝘀𝗽𝗼𝘁 𝗼𝗻 𝗼𝘂𝗿 𝟮𝟬𝟮𝟱 𝗲𝘅𝗽𝗼 𝗳𝗹𝗼𝗼𝗿 – 𝗶𝗻𝗾𝘂𝗶𝗿𝗲 𝘁𝗼 𝘀𝗽𝗼𝗻𝘀𝗼𝗿 𝘁𝗼𝗱𝗮𝘆: https://tinyurl.com/sabm7cx7
⭐️ Interested in taking the stage? 𝗔𝗽𝗽𝗹𝘆 𝘁𝗼 𝗷𝗼𝗶𝗻 𝗼𝘂𝗿 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆-𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝘀𝗽𝗲𝗮𝗸𝗲𝗿 𝗹𝗶𝗻𝗲𝘂𝗽: https://tinyurl.com/sabm7cx7

Be sure to stay tuned for updates from us as we announce our newly joined speakers, sponsors, partners, and more! 👀

🥁 Drum roll please...
We are so excited to kick off our speaker announcements for 2025 and welcome Pamela Gavin, Chief Executive Officer, National Organization for Rare Disorders, Inc. (NORD), to the World Orphan Drug Congress USA's industry-leading speaker lineup❗️

Stay tuned for more announcements from us for our 2025 edition – you won't want to miss this. Plus, beat the crowd by registering today and securing you spot alongside the biggest names in and . Did we mention you can 𝘀𝗮𝘃𝗲 𝘂𝗽 𝘁𝗼 𝟱𝟬% on your tickets when you register as a group? 👀

What are you waiting for? Gather your friends, family, peers, colleagues, and fellow rare disease enthusiasts and 𝘀𝗮𝘃𝗲 $𝟭,𝟳𝟮𝟬 today ➡️ https://tinyurl.com/4x3nwttm

Hospitals & patient advocacy groups, claim your 𝗙𝗥𝗘𝗘 𝗽𝗮𝘀𝘀 here ➡️ https://tinyurl.com/2puserrw

🗓️ April 22-24, 2025
📍 Boston Convention & Exhibition Center

𝘓𝘰𝘰𝘬𝘪𝘯𝘨 𝘵𝘰 𝘨𝘦𝘵 𝘪𝘯𝘷𝘰𝘭𝘷𝘦𝘥? Download our prospectus to learn more about available opportunities ➡️ https://tinyurl.com/3w2jwvew

🗞️ Hot off the Press: World Orphan Drug Congress 2024

Extra, extra, read all about it! 𝗢𝘂𝗿 𝟮𝟬𝟮𝟰 𝗽𝗿𝗲𝘀𝘀 𝗿𝗼𝘂𝗻𝗱𝘂𝗽 𝗶𝘀 𝗵𝗲𝗿𝗲 ➡️ https://tinyurl.com/5ckvzr6x

Browse our press page to discover key takeaways, session highlights, and more from the world's most important orphan drug and rare disease event.

Plus, join us back in Boston next April 22-24 for our 2025 edition! ⭐️

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗮𝘀 𝗮 𝗴𝗿𝗼𝘂𝗽 𝗮𝗻𝗱 𝘀𝗮𝘃𝗲 𝘂𝗽 𝘁𝗼 𝟱𝟬% 𝗼𝗻 𝘁𝗶𝗰𝗸𝗲𝘁𝘀 𝗵𝗲𝗿𝗲 ➡️ https://tinyurl.com/4x3nwttm

A Neglected Health Concern: Rare Diseases in Adults Advocates at WODC 2024 stressed the importance of early detection and treatment of rare diseases in adults.

Legislation Could Improve Access to Specialized Pediatric Health Care Clinical experts and advocates called for improving children's access to essential health care by streamlining Medicaid provider screening and enrollment.

Prioritizing Clinicians’ Mental Health in Rare Disease Care Sharing knowledge helps healthcare professionals provide better care in rare disease, supporting their mental health and reducing stress.

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia - Alterity Therapeutics MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 29 April 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that important new data ...

The CoRDS Registry: Empowering Patients and Advancing Research The CoRDS registry, the largest international rare disease registry, benefits patients and researchers and facilitates data sharing.

Last week, TargetCancer Foundation Chief Executive Officer Jim Palma returned as a speaker at the World Orphan Drugs Congress in Boston. Jim provided the advocacy perspective on a panel titled "Five Headwinds Facing Rare Cancer Drug Developers (and what to do about it)”.

YHEC staff were delighted to be at World Orphan Drugs Congress last week. Here is what Stuart Mealing had to say about his time there.
If you'd like to get in touch, email us at [email protected]

Home | beyondthediagnosis Beyond the Diagnosis unites art and science to raise awareness, educate, and inspire research and innovation of treatments for children living with rare and neglected diseases.  

"Towards a World Health Assembly Resolution on Rare Diseases" – a Day 1 Presentation on 's Rare Disease Advocacy World track with Alexandra Heumber Perry, Chief Executive Officer, Rare Diseases International.

Alexandra brings 20 years’ experience in global health with demonstrated capabilities in patient advocacy and multi-stakeholder partnership, focusing initially on neglected and vulnerable patient populations, notably with Drugs for Neglected Diseases, Médecins sans Frontières, and Union for International Cancer Control and more recently advocating on behalf of specific communities including neurology, myalgic encephalomyelitis, obesity, and haemophilia.

Now's the time to 𝗴𝗲𝘁 𝘆𝗼𝘂𝗿 𝘁𝗶𝗰𝗸𝗲𝘁 𝗯𝗲𝗳𝗼𝗿𝗲 𝘁𝗵𝗲𝘆 𝗿𝗶𝘀𝗲 𝘁𝗼 𝗳𝘂𝗹𝗹 𝗽𝗿𝗶𝗰𝗲 𝗶𝗻 𝗷𝘂𝘀𝘁 𝟰𝟴 𝗵𝗼𝘂𝗿𝘀!

Register & SAVE now 👉 http://tinyurl.com/mr3pryvp

𝗟𝗶𝗺𝗶𝘁𝗲𝗱 𝗙𝗥𝗘𝗘 𝘁𝗶𝗰𝗸𝗲𝘁𝘀 𝗳𝗼𝗿 𝗽𝗵𝗮𝗿𝗺𝗮 & 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗿𝗲𝗺𝗮𝗶𝗻𝗶𝗻𝗴! Claim yours today 👉 https://tinyurl.com/yc47eec9

Breaking News❗️ We're excited to share we're offering 𝗙𝗥𝗘𝗘 𝗽𝗮𝘀𝘀𝗲𝘀 for pharma and biotechs. But don't wait – there are 𝗼𝗻𝗹𝘆 𝟱𝟬 𝗳𝗿𝗲𝗲 𝗽𝗮𝘀𝘀𝗲𝘀 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 to the first who apply and qualify.

🎟️ 𝗚𝗲𝘁 𝘆𝗼𝘂𝗿 𝗙𝗥𝗘𝗘 𝗽𝗮𝘀𝘀 𝘁𝗼𝗱𝗮𝘆: https://tinyurl.com/yc47eec9

The World Orphan Drug Congress USA is coming to the Boston Convention & Exhibition Center in 5 short weeks!
On April 24, catch our all-star panel from our Advanced Therapies Clinical Development track: "𝗦𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗼𝗳 𝗡-𝗼𝗳-𝟭", featuring...

⭐️ Dave Pearce, Chair, International Rare Diseases Research Consortium (IRDiRC)
⭐️ Sarah Glass, PhD, Chief Operating Officer, N-Lorem Foundation
⭐️ P.J. Brooks, Acting Director, Division of Rare Diseases Research Innovation, National Center for Advancing Translational Sciences (NCATS), NIH
⭐️ Larissa Lapteva, MD, MHS, MBA, Associate Director, Division of Clinical Evaluation, Pharmacology, and Toxicology, Office of Tissues and Advanced Therapies, CBER, U.S. Food and Drug Administration

Get in on the action – 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝘁𝗼𝗱𝗮𝘆: http://tinyurl.com/mr3pryvp

Hospitals and patient advocacy groups – 𝗮𝗽𝗽𝗹𝘆 𝗳𝗼𝗿 𝘆𝗼𝘂 𝗙𝗥𝗘𝗘 𝗽𝗮𝘀𝘀: https://tinyurl.com/yc47eec9

Introducing our 2024 Media Partner, the American Society of Pharmacovigilance! ⭐️

Looking to network with key leaders in the space? Look no further than the World Orphan Drug Congress USA.

𝗚𝗲𝘁 𝘆𝗼𝘂𝗿 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝗲𝗱 𝘁𝗶𝗰𝗸𝗲𝘁𝘀 𝗵𝗲𝗿𝗲: http://tinyurl.com/mr3pryvp
Hospitals and patient advocacy groups, 𝗮𝗽𝗽𝗹𝘆 𝗳𝗼𝗿 𝘆𝗼𝘂 𝗰𝗼𝗺𝗽𝗹𝗶𝗺𝗲𝗻𝘁𝗮𝗿𝘆 𝗽𝗮𝘀𝘀 𝗵𝗲𝗿𝗲: https://tinyurl.com/yc47eec9

Day 1 Fireside Chat highlight from our Clinical Development & Regulatory Track: "Patient-first innovation: FDA shifting rare diseases endpoints" with...

Julie Breneiser, Executive Director, Gorlin Syndrome Alliance
Annie Kennedy, Chief of Policy and Advocacy, EveryLife Foundation for Rare Diseases

Reserve your spot today to catch incredible sessions like this at next month's World Orphan Drug Congress USA!

Register & SAVE: http://tinyurl.com/mr3pryvp
Free pass application for hospitals and patient advocacy groups: https://tinyurl.com/yc47eec9

BioNews, our 2024 Media Partner, is a health media company focused on rare diseases and rare patient experiences. BioNews provides an insider’s view into disease and treatment news, condition management information, and community across more than 60+ diseases ❤️‍🩹

A fierce champion of the rare voice, BioNews content is designed to reach, engage, and elevate even the smallest patient populations. They're the only rare news and information property in the U.S. and are committed to the insider’s view into a rare disease or experience. People turn to their content for timely treatment news, management, community and to identify clinical trials opportunities that are a right match for them.

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗮𝗻𝗱 𝘀𝗮𝘃𝗲: http://tinyurl.com/mr3pryvp
𝗖𝗼𝗺𝗽𝗹𝗶𝗺𝗲𝗻𝘁𝗮𝗿𝘆 𝘁𝗶𝗰𝗸𝗲𝘁 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: https://tinyurl.com/yc47eec9

Meet our Media Partner RARE Revolution Magazine!

RARE Revolution Magazine is an independent not-for-profit publication dedicated to elevating the voice of the rare disease community through its website, digital magazine, patient engagement services and RARE Youth Revolution. It produces high-quality articles to support disease awareness and education across stakeholders, sectors and geographies. Featuring compelling voices and leading emerging conversations, RARE Revolution Magazine plays its part in turning the tide for rare disease. 👏

Want to learn more? Register today to meet the RARE Revolution Magazine team in-person on our expo floor next month!

𝗚𝗲𝘁 𝘆𝗼𝘂𝗿 𝘁𝗶𝗰𝗸𝗲𝘁𝘀 𝗵𝗲𝗿𝗲: http://tinyurl.com/mr3pryvp
Hospitals and patient advocacy groups – 𝗮𝗽𝗽𝗹𝘆 𝗳𝗼𝗿 𝘆𝗼𝘂𝗿 𝗰𝗼𝗺𝗽𝗹𝗶𝗺𝗲𝗻𝘁𝗮𝗿𝘆 𝗽𝗮𝘀𝘀 𝗵𝗲𝗿𝗲: https://tinyurl.com/yc47eec9

"𝗚𝗹𝗼𝗯𝗮𝗹 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝘁𝗶𝗺𝗲𝗹𝘆 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 𝗮𝗻𝗱 𝗰𝗮𝗿𝗲 𝗳𝗼𝗿 𝗽𝗲𝗿𝘀𝗼𝗻𝘀 𝗹𝗶𝘃𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗮 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲" – coming to the World Orphan Drug Congress USA stage April 25, with Mary Wang, Programme Director, Rare Diseases International(RDI).

𝘓𝘰𝘰𝘬𝘪𝘯𝘨 𝘵𝘰 𝘭𝘦𝘢𝘳𝘯 𝘢𝘣𝘰𝘶𝘵 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘪𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘳𝘢𝘳𝘦 𝘥𝘪𝘴𝘦𝘢𝘴𝘦 𝘴𝘱𝘢𝘤𝘦? is the place to be! Reserve your spot today to catch eye-opening sessions like Mary's on our Diagnosis track next month at the Boston Convention & Exhibition Center.

𝗚𝗲𝘁 𝘆𝗼𝘂𝗿 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝗲𝗱 𝘁𝗶𝗰𝗸𝗲𝘁: http://tinyurl.com/mr3pryvp
Hospitals and patient advocacy groups, 𝗮𝗽𝗽𝗹𝘆 𝗳𝗼𝗿 𝘆𝗼𝘂𝗿 𝗰𝗼𝗺𝗽𝗹𝗶𝗺𝗲𝗻𝘁𝗮𝗿𝘆 𝗽𝗮𝘀𝘀: https://tinyurl.com/yc47eec9

Highlighting our Media Partner, TREAT-NMD – a global network of experts in the neuromuscular field who work in partnership with organisations and individuals globally to transform diagnosis, treatment and care for people living with neuromuscular diseases 🙌

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗲𝗮𝗿𝗹𝘆-𝗯𝗶𝗿𝗱 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁: http://tinyurl.com/mr3pryvp
𝗖𝗼𝗺𝗽𝗹𝗶𝗺𝗲𝗻𝘁𝗮𝗿𝘆 𝘁𝗶𝗰𝗸𝗲𝘁 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: https://tinyurl.com/yc47eec9

We are proud to welcome our Gold Sponsor, Alexion Pharmaceuticals, to the World Orphan Drug Congress USA 2024!

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology.

🗓️ Mark your calendars and secure your ticket to join us this April 23-25 at the Boston Convention & Exhibition Center.

Our final early-bird ticket discount won't be around long – 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄 𝘁𝗼 𝘀𝗮𝘃𝗲: http://tinyurl.com/mr3pryvp
Hospitals and patient advocacy groups, 𝗮𝗽𝗽𝗹𝘆 𝗳𝗼𝗿 𝘆𝗼𝘂𝗿 𝗰𝗼𝗺𝗽𝗹𝗶𝗺𝗲𝗻𝘁𝗮𝗿𝘆 𝘁𝗶𝗰𝗸𝗲𝘁 𝗵𝗲𝗿𝗲: https://tinyurl.com/yc47eec9

"𝗖𝘂𝗿𝗲𝗔𝗣-𝟰 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗳𝗼𝗿 𝘂𝗹𝘁𝗿𝗮-𝗿𝗮𝗿𝗲 𝗖𝗡𝗦 𝗱𝗶𝘀𝗲𝗮𝘀𝗲" brought to you by World Orphan Drug Congress USA's Day 2 Drug Discovery track!

Featuring:
Maria Picone, Chief Executive Officer, TREND Community
Kasey Edwards, Co-Founder, Community Relations Specialist, Cure AP-4

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄 𝘁𝗼 𝘀𝗮𝘃𝗲 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗲𝗮𝗿𝗹𝘆-𝗯𝗶𝗿𝗱 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁 👉 http://tinyurl.com/mr3pryvp
𝗖𝗼𝗺𝗽𝗹𝗶𝗺𝗲𝗻𝘁𝗮𝗿𝘆 𝘁𝗶𝗰𝗸𝗲𝘁 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 for patient advocacy groups & hospitals 👉 https://tinyurl.com/yc47eec9

"𝗠𝗲𝗮𝘀𝘂𝗿𝗶𝗻𝗴 𝗱𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗶𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀: 𝗗𝗼 𝘄𝗲 𝗵𝗮𝘃𝗲 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝗺𝗲𝗮𝘀𝘂𝗿𝗲𝘀 𝘁𝗼 𝗺𝗲𝗮𝘀𝘂𝗿𝗲 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝘁𝗵𝗶𝗻𝗴𝘀?", a World Orphan Drug Congress USA Day 2 Clinical Development & Regulatory Presentation from Adrian Kielhorn, Senior Director Health Economics and Outcomes Research, Alexion Pharmaceuticals.

You won't want to miss this. 𝗚𝗲𝘁 𝘆𝗼𝘂𝗿 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝗲𝗱 𝘁𝗶𝗰𝗸𝗲𝘁 𝘁𝗼𝗱𝗮𝘆: http://tinyurl.com/mr3pryvp
Patient Advocacy Groups & Hospitals 𝗰𝗼𝗺𝗽𝗹𝗶𝗺𝗲𝗻𝘁𝗮𝗿𝘆 𝘁𝗶𝗰𝗸𝗲𝘁 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: https://tinyurl.com/yc47eec9

We are excited to highlight another can't-miss Keynote Panel hitting the stage this April 25 – "𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝗔𝗰𝗰𝗲𝘀𝘀: 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝗣𝗼𝗹𝗶𝗰𝗶𝗲𝘀 𝗮𝗻𝗱 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 𝗳𝗼𝗿 𝗢𝗿𝗽𝗵𝗮𝗻 𝗗𝗿𝘂𝗴 𝗔𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆", with:

Moderator: Jayson Slotnik, Partner, Health Policy Strategies, LLC
Annie Kennedy, Chief of Policy, Advocacy, & Patient Engagement, Everlife Foundation for Rare Diseases
Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson
Ron Bartek, President, Co-Founder, Friedreich's Ataxia Research Alliance (FARA)

Get your discounted ticket to sit in on this incredible session and so many more this April 23-25 at the Boston Convention & Exhibition Center.

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗮𝗻𝗱 𝘀𝗮𝘃𝗲 𝗵𝗲𝗿𝗲: http://tinyurl.com/mr3pryvp
𝗖𝗼𝗺𝗽𝗹𝗶𝗺𝗲𝗻𝘁𝗮𝗿𝘆 𝘁𝗶𝗰𝗸𝗲𝘁 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗵𝗲𝗿𝗲: https://tinyurl.com/yc47eec9

Presentation highlight! 👉 "𝗠𝗲𝗮𝘀𝘂𝗿𝗶𝗻𝗴 𝗱𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗶𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀: 𝗗𝗼 𝘄𝗲 𝗵𝗮𝘃𝗲 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝗺𝗲𝗮𝘀𝘂𝗿𝗲𝘀 𝘁𝗼 𝗺𝗲𝗮𝘀𝘂𝗿𝗲 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝘁𝗵𝗶𝗻𝗴𝘀?", with...
Adrian Kielhorn, Senior Director, Global HEOR Neurology, Alexion Pharmaceuticals, Inc.

Don't miss out – catch 3 days of incredible sessions like this at World Orphan Drug Congress USA, coming to the Boston Convention & Exhibition Center April 23-25. Plus, tickets are 20% off until this Friday – get yours today!

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲 𝗮𝗻𝗱 𝗦𝗔𝗩𝗘: http://tinyurl.com/mr3pryvp